Loading clinical trials...
Loading clinical trials...
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Conditions
Interventions
Trans Sodium Crocetinate plus SOC
Standard of Care (SOC)
Locations
13
United States
University of California
Irvine, California, United States
Scott Peak, M.D.
Redwood City, California, United States
John Wayne Cancer Institute @ Providence Saint John's Health Center
Santa Monica, California, United States
Piedmont Cancer
Atlanta, Georgia, United States
John B. Amos Cancer Center
Columbus, Georgia, United States
Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Start Date
January 16, 2018
Primary Completion Date
November 6, 2020
Completion Date
November 6, 2020
Last Updated
July 22, 2021
NCT05969860
NCT02800486
NCT05789394
NCT06934889
NCT05283330
NCT00083512
Lead Sponsor
Diffusion Pharmaceuticals Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions